Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC11648 structure
    GC11648BML-277
    CAS: 516480-79-8
    纯度: >98.00%

    A selective DNA damage control kinase inhibitor

  • GC11655 structure
    GC11655Moexipril HCl
    CAS: 82586-52-5
    纯度: >98.00%

    A prodrug form of moexiprilat

  • GC11659 structure
    GC11659R-7050
    CAS: 303997-35-5
    纯度: >99.00%

    R-7050 是一种新型细胞渗透性三唑并喹喔啉化合物,可选择性抑制 TNF-α;诱导细胞信号传导。

  • GC11669 structure
    GC11669Tamoxifen Citrate
    CAS: 54965-24-1
    纯度: >99.50%

    A selective estrogen receptor modulator

  • GC11670 structure
    GC11670Pranoprofen
    CAS: 52549-17-4
    纯度: >98.00%

    An NSAID and COX-1 inhibitor

  • GC11685 structure
    GC11685GW5074
    CAS: 220904-83-6
    纯度: >99.00%

    A potent inhibitor of Raf-1

  • GC11710 structure
    GC11710CFM 4
    CAS: 331458-02-7

    CFM 4 是 CARP-1/APC-2 结合的有效小分子拮抗剂。 CFM 4 阻止 CARP-1 与 APC-2 结合,导致 G2M 细胞周期停滞,并诱导细胞凋亡,IC50 范围为 10-15 μM. CFM 4 还抑制耐药人类乳腺癌细胞的生长。

  • GC11711 structure
    GC11711ONC201
    CAS: 1616632-77-9
    纯度: >99.50% / >98.00%

    ONC201是一种具有口服活性的小分子化合物,属于imipridone类化合物,是多巴胺D2/3受体(DRD2/3)的选择性拮抗剂。

  • GC11716 structure
    GC11716SIRT1/2 Inhibitor IV
    CAS: 14513-15-6
    纯度: >99.00%

    Cell-permeable inhibitor of SIRT1 and SIRT2

  • GC11720 structure
    GC1172017-AAG (KOS953)
    CAS: 75747-14-7
    纯度: >99.00% / >98.00%

    17-AAG(格尔德霉素)是一种天然的苯醌安沙霉素抗生素,是第一个确定的 Hsp90 抑制剂。

  • GC11733 structure
    GC11733PHA-665752
    CAS: 477575-56-7
    纯度: >96.00% / >98.00%

    A selective c-Met inhibitor

  • GC11751 structure
    GC11751QNZ (EVP4593)
    CAS: 545380-34-5
    纯度: >98.00%

    QNZ (EVP4593)是一种高效、选择性核因子κB(NF-κB)信号通路抑制剂,IC 50 值为11nM,具有抗炎功效。

  • GC11762 structure
    GC11762Meloxicam (Mobic)
    CAS: 71125-38-7
    纯度: >99.50%

    A selective COX-2 inhibitor

  • GC11784 structure
    GC11784LCZ696
    CAS: 936623-90-4
    纯度: >99.50%

    A dual angiotensin II receptor antagonist and neprilysin inhibitor

  • GC11786 structure
    GC11786Acetylcysteine
    CAS: 616-91-1
    纯度: >99.00%

    乙酰半胱氨酸是半胱氨酸的 N-乙酰基衍生物。

  • GC11837 structure
    GC11837MI-136
    CAS: 1628316-74-4
    纯度: >98.50%

    A menin-MLL inhibitor

  • GC11869 structure
    GC11869SZL P1-41
    CAS: 222716-34-9
    纯度: >98.00%

    SZL P1-41是一种特异性S期激酶相关蛋白2(Skp2)抑制剂。

  • GC11892 structure
    GC11892AEE788 (NVP-AEE788)
    CAS: 497839-62-0
    纯度: >98.00%

    An inhibitor of EGFR and VEGFR tyrosine kinases

  • GC11895 structure
    GC11895Mevastatin
    CAS: 73573-88-3
    纯度: >99.50%

    An HMG-CoA reductase inhibitor

  • GC11931 structure
    GC11931BKM120
    CAS: 944396-07-0
    纯度: >99.50%

    An inhibitor of class I PI3K isoforms

  • GC11935 structure
    GC11935Escin
    CAS: 6805-41-0
    纯度: >98.00%

    七叶皂苷是一种从七叶树 (Aesculus hippocastanum) 种子中分离出来的三萜皂苷的天然化合物,可用作血管保护性抗炎、抗水肿和抗伤害剂。

  • GC11965 structure
    GC11965(±)-Huperzine A
    CAS: 120786-18-7
    纯度: >98.00%

    A neuroprotective AChE inhibitor

  • GC11971 structure
    GC11971LY2857785
    CAS: 1619903-54-6
    纯度: >98.50%

    A Cdk9 inhibitor

  • GC11973 structure
    GC11973HSP990 (NVP-HSP990)
    CAS: 934343-74-5
    纯度: >98.00%

    An Hsp90 inhibitor